Company intelligence / Profile preview

Respiree

Ownership: Private
Development stage: Commercial

Overview

The RS001 wearable has received US FDA 510(k) clearance, CE mark, TGA approval in Australia. Clinical studies have validated its ability to detect patient deterioration days in advance with >90% accuracy. Ongoing collaborations are expanding the use of its AI-based predictive algorithms for early intervention in cardio-respiratory conditions.

Therapeutic areas: PulmonologyCardiovascular
Modalities: DeviceDigital biomarker platform (AI/ML-driven)Non-pharmacological therapy (remote monitoring)
Industry: Physiological Monitoring

Drug pipeline

1 asset

RS001

Commercial

Indications: Chronic obstructive pulmonary disease, Congestive heart failure

Partnerships

Roche (technology integration partnership announced September 2024)

Beyond the preview

Go deeper on Respiree.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respiree.

Explore the full profile